AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq....
+See More2018-01-07 09:33:00 Sunday ET
Zuckerberg announces his major changes in Facebook's newsfeed algorithm and user authentication. Facebook now has to change the newsfeed filter to prior
2017-10-21 08:45:00 Saturday ET
Netflix stares at higher content costs as Disney and Fox hold merger talks. Disney has held talks to acquire most of 21st Century Fox's business equity.
2019-02-09 08:33:00 Saturday ET
Apple provides positive forward guidance on both revenue and profit forecasts for iPhones, iPads, and MacBooks. In the Christmas 2018 festive season, MacBoo
2019-12-04 14:35:00 Wednesday ET
Many billionaires choose to live below their means with frugal habits and lifestyles. Those people who consistently commit to saving more, spending less, an
2017-02-25 06:44:00 Saturday ET
As the White House economic director, Gary Cohn suggests that the Trump administration will tackle tax cuts after the administration *repeals and replaces*
2020-09-24 10:26:00 Thursday ET
Edge strategies help business leaders improve core products and services in a more cost-effective and less risky way. Alan Lewis and Dan McKone (2016)